Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 317

recruiting
3 968
countries
28
conditions
2 103

3 968 trials match your criteria

Study on Imatinib for Patients with Triple Negative Breast Cancer to Convert it to ER-Positive Breast Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ademetionine

Study of Cetuximab and Avelumab for Patients with Recurrent or Metastatic Head and Neck Cancer with PD-L1 Score 1 or Higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Breast cancer

Recruiting

Study on Post-Neoadjuvant Therapy for Early Breast Cancer Using Ipatasertib, Inavolisib, and Atezolizumab for Patients with High-Risk Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Comparison of dapagliflozin and oral semaglutide effectiveness in type 2 diabetes patients based on insulin resistance or secretion deficit

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Rectal cancer

Recruiting

Study of drug combination (capecitabine, fluorouracil, oxaliplatin, calcium folinate) to prevent cancer recurrence in patients with detectable ctDNA after rectal cancer surgery

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Medulloblastoma

Recruiting

Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab

Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ocrelizumab

Study on Short vs. Long Immunotherapy with Pembrolizumab and Nivolumab for Patients with High-Risk Skin Melanoma After Surgery

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Study of Taletrectinib for Patients with Advanced or Metastatic ROS1 Positive Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Taletrectinib

Study on the Effectiveness of Atenativ for Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Childbirth

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Antithrombin Iii Human
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.